Testosterone Gel

Researchers reported that topical testosterone gel replacement reduced insulin resistance and glycated hemoglobin in men who were deficient in the hormone.
According to Hugh Jones MD of the University of Sheffield in England "This was the first large placebo-controlled study to show that testosterone replacement in hypogonadal men with metabolic syndrome or diabetes improves insulin resistance and glycemic control." Low testosterone is a known risk factor for type 2 diabetes in men. Up to one-third of men with type 2 diabetes are testosterone-deficient, due to aging or treatment for prostate or testicular cancer. Moreover, glycated hemoglobin levels were cut by half a percentage point after six months of treatment, Jones said during a presentation here at at the Society for Endocrinology annual meeting.

Obesity drug market in decline

Poor efficacy and negative side effects will have a detrimental effect on the sale and development of obesity drugs, according to a forecast by Datamonitor. Obesity is partly the result of lifestyle factors, such as exercise, diet, and increases in the proportion of sedentary jobs. The market for anti-obesity drugs has proved far more difficult to conquer than most companies expected. In 2006, that market segment generated sales of over $1300m worldwide. There have been problems in marketing products, with concerns over safety and efficacy having a negative impact on sales. There have been major disappointments, but some commercial opportunities remain.